Reuters logo
BRIEF-EMA validates Bristol-Myers' type II variation application for Opdivo for treatment of patients with resected high-risk advanced melanoma
October 30, 2017 / 11:15 AM / a month ago

BRIEF-EMA validates Bristol-Myers' type II variation application for Opdivo for treatment of patients with resected high-risk advanced melanoma

Oct 30 (Reuters) - Bristol-myers Squibb Co

* European Medicines Agency validates Bristol-Myers Squibb’s type II variation application for Opdivo (nivolumab) for treatment of patients with resected high-risk advanced melanoma

* Bristol-Myers Squibb Co - ‍Validation of type II variation application confirms submission is complete and begins EMA’s centralized review process​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below